We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alifax Presents First Automated System for Bacterial Culture and Susceptibility Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 22 Apr 2022
Image: Alfred 60AST is the first automated system for bacterial culture and susceptibility testing (Photo courtesy of Alifax)
Image: Alfred 60AST is the first automated system for bacterial culture and susceptibility testing (Photo courtesy of Alifax)

Alifax S.r.l. (Padua, Italy) presented the world’s first automated system for bacterial culture and susceptibility testing at the 32nd edition of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) held in Lisbon, Portugal on 23 - 26 April 2022. ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together more than 14,000 colleagues from all over the world.

At this year’s ECCMID, Alifax presented Alfred 60AST, the first fully automated system able to perform bacterial culture, RAA and susceptibility testing by automating the whole process of sample inoculation, reading and result transmission. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity. The CE - IVD Marked Alfred 60AST monitors the growth phases of bacteria from the inoculum step into specific culture broths providing real time growth curves and quantitative bacterial count results in CFU/ml.

Alifax also demonstrated HB&L, the first analyzer for bacterial culture and susceptibility testing in human biological fluids and urine. HB&L is the first analyser able to perform bacterial culture, RAA test and susceptibility testing on samples such as urine, sterile or non sterile fluids and other biological samples. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity.

Related Links:
Alifax S.r.l.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more